IPO Listed — 17 Dec 2025
Listing Price: ₹490
Nephrocare Health Services IPO GMP History | Listing Price ₹490 & Kostak Rate
Nephrocare Health Services IPO has been listed on December 17, 2025 at a listing price of ₹490, against the issue price of ₹460 — a gain of ₹30 (+6.52%). The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Nephrocare Health Services IPO raised ₹871.05 Cr. through its IPO at a price band of ₹438 – 460 per share, with a lot size of 32 shares. The IPO was open for subscription from 10 Dec 2025 to 12 Dec 2025.
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| No GMP history available yet. | |||||
Nephrocare Health Services IPO Dates
| Event | Date |
|---|---|
| Open Date | 10 Dec, 2025 |
| Close Date | 12 Dec, 2025 |
| Allotment Date | 15 Dec, 2025 |
| Refund Date | 16 Dec, 2025 |
| Credit to Demat | 16 Dec, 2025 |
| Listing Date | 17 Dec, 2025 |
Nephrocare Health Services IPO Actual Listing Price
| Basis | Value |
|---|---|
| Issue Price | ₹460 |
| Actual Listing Price | ₹490 (+6.52%) |
| Listing Gain / Loss | +₹30 per share |
| Listing Date | 17 Dec, 2025 |
Is Nephrocare Health Services IPO GMP Reliable?
Grey market premium for Nephrocare Health Services IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the Nephrocare Health Services IPO full review for a fundamentals-based assessment before making any grey market trades.
Nephrocare Health Services IPO IPO Kostak Rate Explained
The Kostak rate for Nephrocare Health Services IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Nephrocare Health Services IPO
The company primarily offers dialysis services, including haemodialysis and related renal care treatments, supported by trained medical staff and modern equipment. Its business model is asset-light and partnership-driven, where it collaborates with hospitals to operate dialysis centres within their premises, reducing capital expenditure while expanding reach. Revenue is generated through long-term service agreements and patient volumes. Promoted by professionals with domain expertise, Nephrocare focuses on operational efficiency, affordability, and scalability, aiming to address the rising demand for kidney care services in both urban and semi-urban regions.
Frequently Asked Questions about Nephrocare Health Services IPO
What is the GMP of Nephrocare Health Services IPO?
The current Grey Market Premium (GMP) of Nephrocare Health Services IPO is not yet started or active in the market.
What is the Kostak Price of Nephrocare Health Services IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Nephrocare Health Services IPO is currently not available.
What is the Subject to Sauda Price of Nephrocare Health Services IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.
What was the actual listing price of Nephrocare Health Services IPO?
Nephrocare Health Services IPO listed on December 17, 2025 at ₹490, against the issue price of ₹460 — a gain of +6.52%.
How did the GMP of Nephrocare Health Services IPO trend before listing?
The GMP of Nephrocare Health Services IPO was stable in its final days before listing. View the day-wise table above for the complete GMP history.
Explore Nephrocare Health Services IPO Further
For a complete picture before making your investment decision, explore these resources:
Discussion 0
No comments yet
Be the first to share your thoughts!